# Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

> **NCT04827875** · PHASE1 · COMPLETED · sponsor: **AiViva BioPharma, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Keloid
- Scar
- Incision
- Excision Margin

## Interventions

- **DRUG:** AIV001

## Key facts

- **NCT ID:** NCT04827875
- **Lead sponsor:** AiViva BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-23
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827875, "Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04827875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*